Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.
Neutrophilic eccrine hidradenitis has been described in patients with acute myelogenous leukemia and other malignant diseases, usually during chemotherapy. We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine. Dapsone, 100 mg daily, was initiated 48 hours before the patient's third treatment with lomustine and was continued for 14 days. This regimen was successful in suppressing the reaction during the first course and three subsequent courses of lomustine.
Division of Dermatology, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
N H
NH
Shear
S R
SR
Knowles
L
L
Shapiro
P
P
Poldre
D000970:Antineoplastic Agents / Q000009:adverse effects; D003622:Dapsone / Q000627:therapeutic use*; D016575:Hidradenitis / Q000139:chemically induced / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008130:Lomustine / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D000970:Antineoplastic Agents; D008130:Lomustine; D003622:Dapsone